Hub : Traits :

Diabetes (self-reported)

91 significantly associated models · 35 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	119761038	120687115	2	1	7.7e-09	5.5e-09	1.0e+00	100	NOTCH2
2	1	213759712	215206914	1	1	2.6e-07	1.3e-07	1.2e-02	77	SMYD2
3	2	26883355	28402863	5	1	1.4e-09	2.2e-10	1.0e+00	100	FNDC4
4	3	22998569	23879862	1	1	9.3e-09	8.6e-10	1.1e-02	83	UBE2E2
5	3	48757291	50833360	5	2	1.9e-09	2.7e-09	5.0e-03	78	RBM6 TCTA
6	3	185112300	185786406	1	1	3.9e-19	4.8e-24	9.1e-07	76	IGF2BP2
7	4	5575751	7002344	1	1	1.4e-15	1.5e-16	3.6e-04	81	WFS1
8	6	6582123	8009760	1	1	2.8e-11	3.0e-07	2.0e-03	64	SSR1
9	7	27623776	28468319	1	1	2.5e-13	4.2e-15	1.9e-03	84	JAZF1
10	7	73624615	74494207	1	1	3.5e-08	1.3e-07	1.0e+00	100	PMS2P5
11	8	40811597	42450441	1	2	1.9e-10	7.4e-12	1.7e-01	96	ANK1
12	10	80443273	81901722	1	1	4.3e-10	6.2e-12	3.7e-04	73	ZCCHC24
13	10	93657148	95151622	3	1	1.3e-15	5.6e-16	6.7e-02	95	EIF2S2P3
14	10	113511441	115622375	2	1	1.5e-36	2.2e-124	2.1e-95	24	TCF7L2
15	11	16709350	18106069	3	1	8.9e-10	1.4e-10	1.0e+00	100	KCNJ11
16	15	75648650	76164348	1	1	1.1e-07	2.0e-05	1.9e-02	70	SNUPN
17	16	52772129	54210447	1	1	1.7e-07	1.2e-17	3.3e-16	9	RBL2
18	19	12309739	13750618	4	1	1.1e-08	7.0e-08	6.5e-01	99	DAND5

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Type 2 Diabetes (T2D) (2018)	32.52	19	18	40.0	0.99	3.3e-18	ANK1 DAND5 EIF2S2P3 FNDC4 IGF2BP2 JAZF1 KCNJ11 NOTCH2 PMS2P5 RBL2 RBM6 SMYD2 SNUPN SSR1 TCF7L2 TCTA UBE2E2 WFS1 ZCCHC24
Diabetes diagnosed by doctor	29.87	19	17	37.8	1.00	3.0e-21	ANK1 DAND5 EIF2S2P3 FNDC4 IGF2BP2 JAZF1 KCNJ11 NOTCH2 PMS2P5 RBL2 RBM6 SMYD2 SNUPN SSR1 TCF7L2 TCTA UBE2E2 WFS1 ZCCHC24
Medication: Metformin	21.84	17	8	17.8	0.99	2.0e-15	ANK1 DAND5 EIF2S2P3 FNDC4 IGF2BP2 JAZF1 KCNJ11 PMS2P5 RBL2 RBM6 SNUPN SSR1 TCF7L2 TCTA UBE2E2 WFS1 ZCCHC24
Triglycerides	20.71	1	1	2.2	0.00	1.0e+00	FNDC4
Type 2 Diabetes (T2D) (2012)	15.64	10	5	11.1	0.98	1.0e-06	ANK1 EIF2S2P3 IGF2BP2 JAZF1 KCNJ11 SSR1 TCF7L2 UBE2E2 WFS1 ZCCHC24
Diabetes (father)	15.18	8	3	6.7	0.99	1.4e-07	ANK1 EIF2S2P3 FNDC4 IGF2BP2 JAZF1 SSR1 TCF7L2 WFS1
Diabetes (mother)	13.44	8	4	8.9	0.99	4.3e-07	ANK1 DAND5 EIF2S2P3 FNDC4 IGF2BP2 TCF7L2 UBE2E2 WFS1
Medication: Gliclazide	11.37	7	2	4.4	0.99	9.3e-06	EIF2S2P3 IGF2BP2 JAZF1 KCNJ11 TCF7L2 UBE2E2 WFS1
Illnesses of siblings: Diabetes	8.32	6	2	4.4	1.00	2.0e-05	EIF2S2P3 IGF2BP2 PMS2P5 RBM6 TCF7L2 WFS1
Fasting Glucose	7.52	2	1	2.2	0.00	1.0e+00	FNDC4 SMYD2
Alcohol intake frequency.	7.20	4	4	8.9	0.15	8.5e-01	FNDC4 PMS2P5 RBM6 TCTA
Pulse rate, automated reading	6.76	7	5	11.1	0.50	2.6e-01	EIF2S2P3 FNDC4 JAZF1 RBL2 RBM6 TCTA WFS1
Eye problems/disorders: Diabetes related eye disease	6.01	3	0	0.0	0.00	1.0e+00	IGF2BP2 TCF7L2 WFS1
High cholesterol (Self-reported)	5.97	1	1	2.2	0.00	1.0e+00	FNDC4
Gout (self-reported)	5.54	1	1	2.2	0.00	1.0e+00	FNDC4
Cholesterol lowering medication	5.29	2	1	2.2	0.00	1.0e+00	FNDC4 TCF7L2
Medication: Allopurinol	5.24	1	1	2.2	0.00	1.0e+00	FNDC4
Medication: Cholesterol lowering	5.06	4	1	2.2	0.25	7.5e-01	FNDC4 IGF2BP2 TCF7L2 TCTA
Waist Hip Ratio (WHR)	4.77	9	7	15.6	0.98	5.3e-06	EIF2S2P3 IGF2BP2 JAZF1 KCNJ11 RBL2 SNUPN TCF7L2 TCTA ZCCHC24
Medication: Atorvastatin	4.76	2	1	2.2	0.00	1.0e+00	FNDC4 TCF7L2
Birth weight	4.39	4	2	4.4	0.06	9.3e-01	ANK1 EIF2S2P3 SMYD2 SSR1
Impedance of arm (left)	4.37	7	4	8.9	-0.08	8.6e-01	DAND5 FNDC4 JAZF1 KCNJ11 RBM6 TCF7L2 TCTA
Impedance of whole body	4.24	7	4	8.9	0.09	8.5e-01	FNDC4 JAZF1 KCNJ11 NOTCH2 PMS2P5 RBM6 TCF7L2
Impedance of arm (right)	4.23	7	4	8.9	-0.09	8.5e-01	DAND5 FNDC4 JAZF1 KCNJ11 RBM6 TCF7L2 TCTA
Arm fat-free mass (right)	4.12	7	3	6.7	0.56	1.9e-01	FNDC4 JAZF1 RBL2 RBM6 SNUPN SSR1 TCTA
Body mass index (BMI)	4.07	7	4	8.9	0.09	8.5e-01	FNDC4 JAZF1 KCNJ11 PMS2P5 RBM6 TCF7L2 TCTA
Arm predicted mass (left)	4.06	7	2	4.4	0.56	1.9e-01	FNDC4 JAZF1 RBL2 RBM6 SNUPN SSR1 TCTA
Arm predicted mass (right)	4.04	7	2	4.4	0.56	1.9e-01	FNDC4 JAZF1 RBL2 RBM6 SNUPN SSR1 TCTA
Number of treatments/medications taken	4.03	3	1	2.2	0.00	1.0e+00	FNDC4 PMS2P5 RBM6
Arm fat-free mass (left)	4.01	7	2	4.4	0.57	1.8e-01	FNDC4 JAZF1 RBL2 RBM6 SNUPN SSR1 TCTA
Number of self-reported non-cancer illnesses	4.00	5	2	4.4	0.50	3.9e-01	FNDC4 IGF2BP2 JAZF1 PMS2P5 RBM6
Crohns Disease (2017)	3.97	6	2	4.4	-0.65	1.6e-01	FNDC4 JAZF1 NOTCH2 PMS2P5 RBM6 TCTA
Breast Cancer	3.97	5	1	2.2	-0.60	2.8e-01	DAND5 NOTCH2 PMS2P5 SNUPN TCF7L2
Leg fat percentage (left)	3.96	7	3	6.7	0.35	4.4e-01	PMS2P5 RBL2 RBM6 SNUPN TCF7L2 TCTA ZCCHC24
Medication: Simvastatin	3.93	2	1	2.2	0.00	1.0e+00	FNDC4 TCF7L2
Pulse rate	3.87	3	2	4.4	0.00	1.0e+00	FNDC4 RBL2 TCTA
Trunk fat-free mass	3.82	6	5	11.1	0.47	3.5e-01	FNDC4 JAZF1 RBL2 RBM6 SNUPN SSR1
Trunk predicted mass	3.82	6	5	11.1	0.47	3.4e-01	FNDC4 JAZF1 RBL2 RBM6 SNUPN SSR1
Whole body water mass	3.81	7	4	8.9	0.47	2.8e-01	FNDC4 JAZF1 RBL2 RBM6 SNUPN SSR1 TCTA
Overall health rating	3.80	3	1	2.2	0.00	1.0e+00	PMS2P5 RBL2 RBM6
Leg fat mass (left)	3.79	6	3	6.7	0.35	4.9e-01	FNDC4 PMS2P5 RBM6 TCF7L2 TCTA ZCCHC24
Leg fat percentage (right)	3.78	7	3	6.7	0.36	4.3e-01	PMS2P5 RBL2 RBM6 SNUPN TCF7L2 TCTA ZCCHC24
Blood Red Count	3.75	7	3	6.7	0.88	8.9e-03	DAND5 EIF2S2P3 FNDC4 IGF2BP2 RBM6 SNUPN TCTA
Alcohol intake versus 10 years previously	3.72	2	2	4.4	0.00	1.0e+00	FNDC4 RBM6
Whole body fat-free mass	3.71	7	4	8.9	0.48	2.8e-01	FNDC4 JAZF1 RBL2 RBM6 SNUPN SSR1 TCTA
Impedance of leg (left)	3.68	7	4	8.9	0.06	9.0e-01	FNDC4 JAZF1 KCNJ11 NOTCH2 PMS2P5 RBL2 RBM6
Age at last live birth	3.68	2	1	2.2	0.00	1.0e+00	EIF2S2P3 RBM6
BMI	3.66	9	7	15.6	0.18	6.4e-01	DAND5 FNDC4 JAZF1 KCNJ11 PMS2P5 RBM6 TCF7L2 TCTA ZCCHC24
Leg fat mass (right)	3.66	6	3	6.7	0.35	5.0e-01	FNDC4 PMS2P5 RBM6 TCF7L2 TCTA ZCCHC24
Basal metabolic rate	3.65	8	3	6.7	0.33	4.3e-01	FNDC4 JAZF1 RBL2 RBM6 SNUPN SSR1 TCF7L2 TCTA
Blood Platelet Count	3.63	7	4	8.9	-0.57	1.8e-01	EIF2S2P3 FNDC4 IGF2BP2 KCNJ11 SNUPN UBE2E2 ZCCHC24
Impedance of leg (right)	3.63	6	5	11.1	-0.16	7.6e-01	FNDC4 JAZF1 KCNJ11 PMS2P5 RBL2 RBM6
Medication for cholesterol, blood pressure or diabetes	3.62	4	0	0.0	-0.53	4.7e-01	FNDC4 IGF2BP2 RBM6 TCTA
Long-standing illness, disability or infirmity	3.61	3	0	0.0	0.00	1.0e+00	IGF2BP2 PMS2P5 RBM6
Taking other prescription medications	3.58	2	1	2.2	0.00	1.0e+00	PMS2P5 RBM6
Height	3.45	8	7	15.6	0.23	5.9e-01	DAND5 FNDC4 JAZF1 KCNJ11 RBL2 SNUPN SSR1 UBE2E2
Fluid intelligence score	3.45	4	1	2.2	-0.66	3.4e-01	KCNJ11 RBL2 RBM6 TCTA
Waist circumference	3.40	6	3	6.7	0.45	3.7e-01	FNDC4 PMS2P5 RBM6 TCF7L2 TCTA ZCCHC24
Weight	3.35	6	3	6.7	0.31	5.5e-01	FNDC4 PMS2P5 RBL2 RBM6 TCF7L2 TCTA
Standing height	3.35	7	6	13.3	0.25	5.8e-01	DAND5 FNDC4 JAZF1 KCNJ11 RBL2 SNUPN SSR1
Comparative height size at age 10	3.34	7	4	8.9	0.34	4.6e-01	EIF2S2P3 FNDC4 JAZF1 KCNJ11 RBL2 SNUPN UBE2E2
Leg fat-free mass (left)	3.24	5	3	6.7	0.39	5.1e-01	FNDC4 RBL2 RBM6 SNUPN TCTA
Leg predicted mass (left)	3.23	4	3	6.7	0.36	6.4e-01	FNDC4 RBL2 RBM6 SNUPN
Illnesses of mother	3.22	2	0	0.0	0.00	1.0e+00	IGF2BP2 TCTA
Age at First Birth	3.20	2	2	4.4	0.00	1.0e+00	RBM6 TCTA
Cardiovascular Disease	3.20	5	3	6.7	0.50	3.9e-01	FNDC4 IGF2BP2 KCNJ11 PMS2P5 TCTA
Leg fat-free mass (right)	3.19	4	3	6.7	0.32	6.8e-01	FNDC4 RBL2 RBM6 SNUPN
Leg predicted mass (right)	3.19	4	3	6.7	0.32	6.8e-01	FNDC4 RBL2 RBM6 SNUPN
Medication for cholesterol	3.10	2	1	2.2	0.00	1.0e+00	FNDC4 RBL2
Crohns Disease (2012)	3.09	4	0	0.0	-0.99	6.2e-03	FNDC4 NOTCH2 RBM6 TCTA
Wheeze or whistling in the chest in last year	3.07	1	1	2.2	0.00	1.0e+00	RBM6
Verbal and Numeric Reasoning (VNR)	3.06	3	2	4.4	0.00	1.0e+00	RBL2 RBM6 TCTA
Intelligence (Savage-Jansen 2018)	3.03	3	2	4.4	0.00	1.0e+00	RBL2 RBM6 TCTA
Age at first live birth	2.99	2	1	2.2	0.00	1.0e+00	RBM6 TCTA
Arm fat mass (left)	2.97	5	2	4.4	0.35	5.6e-01	FNDC4 PMS2P5 RBM6 TCF7L2 TCTA
Arm fat mass (right)	2.96	5	2	4.4	0.34	5.7e-01	FNDC4 PMS2P5 RBM6 TCF7L2 TCTA
Qualifications: A levels/AS levels or equivalent	2.92	2	1	2.2	0.00	1.0e+00	RBM6 TCTA
Whole body fat mass	2.91	4	2	4.4	0.21	7.9e-01	PMS2P5 RBM6 TCF7L2 TCTA
Heel bone mineral density (BMD) T-score, automated (left)	2.90	3	2	4.4	0.00	1.0e+00	PMS2P5 RBM6 TCTA
Blood White Count	2.85	4	3	6.7	-0.91	9.0e-02	FNDC4 RBM6 SNUPN ZCCHC24
Medication: Aspirin	2.82	1	0	0.0	0.00	1.0e+00	IGF2BP2
Birth weight of first child	2.74	2	0	0.0	0.00	1.0e+00	RBL2 SSR1
Systolic Blood Pressure	2.68	6	3	6.7	0.67	1.4e-01	FNDC4 JAZF1 KCNJ11 PMS2P5 TCF7L2 TCTA
Sitting height	2.68	7	5	11.1	0.00	9.9e-01	FNDC4 JAZF1 RBL2 SNUPN SSR1 UBE2E2 ZCCHC24
Hip circumference	2.67	5	3	6.7	-0.13	8.3e-01	FNDC4 PMS2P5 RBL2 RBM6 TCF7L2
Irritable Bowel Disease (IBD)	2.66	3	1	2.2	0.00	1.0e+00	FNDC4 PMS2P5 RBM6
Body fat percentage	2.63	6	2	4.4	0.23	6.6e-01	PMS2P5 RBM6 SNUPN TCF7L2 TCTA ZCCHC24
Medication: Aspirin	2.61	1	0	0.0	0.00	1.0e+00	IGF2BP2
Vascular/heart problems diagnosed by doctor	2.61	5	1	2.2	-0.95	1.3e-02	IGF2BP2 KCNJ11 PMS2P5 RBL2 TCTA
Mouth/teeth dental problems: Dentures	2.52	3	0	0.0	0.00	1.0e+00	FNDC4 PMS2P5 RBM6
Forced expiratory volume in 1-second (FEV1), predicted	2.52	2	1	2.2	0.00	1.0e+00	JAZF1 KCNJ11
High blood pressure	2.51	4	1	2.2	1.00	2.5e-03	KCNJ11 PMS2P5 RBL2 TCTA
Qualifications: College or University degree	2.51	2	1	2.2	0.00	1.0e+00	RBL2 RBM6
Trunk fat mass	2.47	5	2	4.4	0.38	5.3e-01	JAZF1 PMS2P5 RBM6 TCF7L2 TCTA
Hypertension (Self-reported)	2.47	4	1	2.2	1.00	1.1e-03	KCNJ11 PMS2P5 RBL2 TCTA
Arm fat percentage (left)	2.47	4	1	2.2	0.17	8.3e-01	PMS2P5 RBM6 TCF7L2 TCTA
Medication: Blood pressure	2.47	3	0	0.0	0.00	1.0e+00	KCNJ11 PMS2P5 TCTA
Heel T-Score	2.45	7	4	8.9	0.53	2.2e-01	IGF2BP2 JAZF1 PMS2P5 RBM6 SMYD2 SSR1 TCTA
Qualifications: NVQ or HND or HNC or equivalent	2.44	1	0	0.0	0.00	1.0e+00	RBM6
Heel bone mineral density (BMD) T-score, automated (right)	2.43	2	2	4.4	0.00	1.0e+00	RBM6 TCTA
Lung FVC	2.39	6	3	6.7	-0.78	6.9e-02	FNDC4 IGF2BP2 JAZF1 SNUPN SSR1 ZCCHC24
Arm fat percentage (right)	2.37	4	1	2.2	0.16	8.4e-01	PMS2P5 RBM6 TCF7L2 TCTA
Ever highly irritable/argumentative for 2 days	2.36	2	0	0.0	0.00	1.0e+00	RBM6 SNUPN
Diastolic blood pressure, automated reading	2.18	4	2	4.4	0.38	6.2e-01	PMS2P5 RBM6 TCF7L2 TCTA
Illnesses of siblings	2.17	1	0	0.0	0.00	1.0e+00	IGF2BP2
Relative age of first facial hair	2.06	2	1	2.2	0.00	1.0e+00	FNDC4 PMS2P5
Trunk fat percentage	2.06	4	1	2.2	0.92	8.2e-02	PMS2P5 RBM6 TCTA ZCCHC24
Mood swings	2.03	1	0	0.0	0.00	1.0e+00	RBM6
Relative age voice broke	2.02	2	0	0.0	0.00	1.0e+00	PMS2P5 TCTA
Qualifications: None of the above	2.02	2	1	2.2	0.00	1.0e+00	RBL2 RBM6
Medication: Blood pressure	2.00	1	0	0.0	0.00	1.0e+00	PMS2P5
Age when periods started (menarche)	1.98	2	1	2.2	0.00	1.0e+00	DAND5 PMS2P5
Respiratory disease	1.97	3	0	0.0	0.00	1.0e+00	EIF2S2P3 JAZF1 RBM6
Knee pain experienced in last month	1.97	2	0	0.0	0.00	1.0e+00	RBM6 ZCCHC24
Commuting to job workplace: Cycle	1.97	2	0	0.0	0.00	1.0e+00	RBL2 SNUPN
Forced vital capacity (FVC), Best measure	1.96	5	2	4.4	-0.14	8.2e-01	JAZF1 SMYD2 SNUPN SSR1 ZCCHC24
Forced vital capacity (FVC)	1.93	4	1	2.2	-0.51	4.9e-01	SMYD2 SNUPN SSR1 ZCCHC24
Health satisfaction	1.92	1	0	0.0	0.00	1.0e+00	RBM6
Mother's age at death	1.91	1	0	0.0	0.00	1.0e+00	SNUPN
Forced expiratory volume in 1-second (FEV1), Best measure	1.90	3	0	0.0	0.00	1.0e+00	IGF2BP2 SNUPN ZCCHC24
Financial situation satisfaction	1.90	1	0	0.0	0.00	1.0e+00	RBM6
Bipolar Disorder (2018)	1.89	1	0	0.0	0.00	1.0e+00	FNDC4
High blood pressure (siblings)	1.89	1	0	0.0	0.00	1.0e+00	FNDC4
Forced expiratory volume in 1-second (FEV1)	1.88	4	0	0.0	-0.97	2.6e-02	IGF2BP2 SMYD2 SNUPN ZCCHC24
Asthma	1.88	3	0	0.0	0.00	1.0e+00	EIF2S2P3 JAZF1 RBM6
Age started oral contraceptive pill	1.88	1	0	0.0	0.00	1.0e+00	RBM6
Mouth/teeth dental problems: Bleeding gums	1.83	1	0	0.0	0.00	1.0e+00	WFS1
Asthma (self-reported)	1.83	3	0	0.0	0.00	1.0e+00	EIF2S2P3 JAZF1 RBM6
Systolic blood pressure, automated reading	1.82	3	0	0.0	0.00	1.0e+00	KCNJ11 PMS2P5 TCTA
Medication: Ventolin 100micrograms inhaler	1.82	1	0	0.0	0.00	1.0e+00	RBM6
Medication: Seretide 50 evohaler	1.82	1	0	0.0	0.00	1.0e+00	RBM6
Schizophrenia vs Biploar Disorder	1.81	2	0	0.0	0.00	1.0e+00	FNDC4 RBM6
Qualifications: nursing, teaching	1.73	2	0	0.0	0.00	1.0e+00	RBM6 TCF7L2
Miserableness	1.72	1	1	2.2	0.00	1.0e+00	RBM6
Alcohol drinker status: Previous	1.72	1	0	0.0	0.00	1.0e+00	DAND5
Allergy	1.71	1	0	0.0	0.00	1.0e+00	JAZF1
Leg pain on walking	1.68	1	0	0.0	0.00	1.0e+00	RBM6
Fed-up feelings	1.67	1	0	0.0	0.00	1.0e+00	RBM6
Peak expiratory flow (PEF)	1.67	2	0	0.0	0.00	1.0e+00	IGF2BP2 SNUPN
Prospective memory result	1.65	1	0	0.0	0.00	1.0e+00	RBM6
Hayfever, allergic rhinitis or eczema	1.64	2	0	0.0	0.00	1.0e+00	FNDC4 JAZF1
Mean time to correctly identify matches	1.62	2	0	0.0	0.00	1.0e+00	RBM6 TCTA
Number of live births	1.61	1	0	0.0	0.00	1.0e+00	RBM6
Breastfed as a baby	1.61	2	0	0.0	0.00	1.0e+00	RBM6 TCTA
Mouth/teeth dental problems	1.59	1	0	0.0	0.00	1.0e+00	PMS2P5
HDL Cholesterol	1.58	1	0	0.0	0.00	1.0e+00	RBM6
Allergy or Eczema	1.56	2	0	0.0	0.00	1.0e+00	FNDC4 JAZF1
Osteoporosis (self-reported)	1.56	2	0	0.0	0.00	1.0e+00	FNDC4 TCTA
Depressed Affect (Nagel 2018)	1.55	1	0	0.0	0.00	1.0e+00	RBM6
Illnesses of father: Heart disease	1.54	1	0	0.0	0.00	1.0e+00	ZCCHC24
Past tobacco smoking	1.52	1	0	0.0	0.00	1.0e+00	DAND5
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.52	2	0	0.0	0.00	1.0e+00	IGF2BP2 JAZF1
Other serious medical condition/disability diagnosed by doctor	1.48	1	0	0.0	0.00	1.0e+00	PMS2P5
Hair/balding pattern: Pattern 4	1.48	1	0	0.0	0.00	1.0e+00	NOTCH2
Smoking status: Previous	1.47	1	0	0.0	0.00	1.0e+00	DAND5
Blood Eosinophil Count	1.46	3	3	6.7	0.00	1.0e+00	EIF2S2P3 JAZF1 RBM6
Chronic bronchitis/emphysema (mother)	1.40	1	0	0.0	0.00	1.0e+00	RBM6
Reaction Time	1.38	1	0	0.0	0.00	1.0e+00	TCTA
Pain experienced in last month	1.37	1	0	0.0	0.00	1.0e+00	RBM6
Medication: Co-codamol	1.36	1	0	0.0	0.00	1.0e+00	RBM6
Hand grip strength (right)	1.36	2	0	0.0	0.00	1.0e+00	FNDC4 SNUPN
Frequency of tiredness / lethargy in last 2 weeks	1.36	1	0	0.0	0.00	1.0e+00	SNUPN
Average weekly beer plus cider intake	1.34	1	0	0.0	0.00	1.0e+00	RBM6
Comparative body size at age 10	1.30	1	0	0.0	0.00	1.0e+00	FNDC4
Ulcerative Colitis (UC)	1.24	1	0	0.0	0.00	1.0e+00	RBM6
Frequency of tenseness / restlessness in last 2 weeks	1.24	1	0	0.0	0.00	1.0e+00	RBM6
Pack years adult smoking proportion	1.18	1	0	0.0	0.00	1.0e+00	PMS2P5
Hypothyroidism/myxoedema (self-reported)	1.17	1	0	0.0	0.00	1.0e+00	IGF2BP2
Schizophrenia (2014)	1.15	1	0	0.0	0.00	1.0e+00	KCNJ11
Worrier / anxious feelings	1.14	1	0	0.0	0.00	1.0e+00	TCF7L2
Hypothyroidism (self reported)	1.12	1	0	0.0	0.00	1.0e+00	IGF2BP2
Pack years of smoking	1.09	1	0	0.0	0.00	1.0e+00	PMS2P5
LDL Cholesterol	1.08	1	0	0.0	0.00	1.0e+00	FNDC4
Smoking Status	1.08	1	0	0.0	0.00	1.0e+00	KCNJ11
Neuroticism score	0.96	1	0	0.0	0.00	1.0e+00	RBM6
Neuroticism	0.93	1	0	0.0	0.00	1.0e+00	RBM6
Lung FEV1/FVC ratio	0.80	1	1	2.2	0.00	1.0e+00	IGF2BP2
Tanning	0.71	3	3	6.7	0.00	1.0e+00	FNDC4 JAZF1 NOTCH2
Hair Pigment	0.63	4	2	4.4	-0.06	9.4e-01	FNDC4 JAZF1 SSR1 ZCCHC24

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Ovary	1	0.110	1.8
GTEx	Artery Aorta	3	0.101	1.7
GTEx	Brain Cerebellar Hemisphere	2	0.134	1.7
GTEx	Brain Cerebellum	1	0.050	1.7
GTEx	Brain Cortex	3	0.290	1.7
GTEx	Thyroid	4	0.100	1.7
GTEx	Adipose Subcutaneous	2	0.057	1.6
GTEx	Adipose Visceral Omentum	0	0.000	1.6
GTEx	Artery Tibial	0	0.000	1.6
GTEx	Breast Mammary Tissue	0	0.000	1.6
GTEx	Breast Mammary Tissue (Male)	0	0.000	1.6
GTEx	Breast Mammary Tissue (Female)	0	0.000	1.6
GTEx	Cells EBV-transformed lymphocytes	0	0.000	1.6
GTEx	Cells Transformed fibroblasts	3	0.071	1.6
GTEx	Colon Sigmoid	0	0.000	1.6
GTEx	Colon Transverse	0	0.000	1.6
GTEx	Esophagus Mucosa	3	0.090	1.6
GTEx	Esophagus Muscularis	3	0.093	1.6
GTEx	Heart Atrial Appendage	2	0.127	1.6
GTEx	Lung	1	0.035	1.6
GTEx	Muscle Skeletal	2	0.069	1.6
GTEx	Nerve Tibial	1	0.023	1.6
GTEx	Pancreas	1	0.061	1.6
GTEx	Pituitary	1	0.090	1.6
GTEx	Prostate	1	0.120	1.6
GTEx	Skin Not Sun Exposed Suprapubic	2	0.081	1.6
GTEx	Skin Sun Exposed Lower leg	3	0.082	1.6
GTEx	Spleen	1	0.071	1.6
GTEx	Testis	5	0.158	1.6
GTEx	Vagina	0	0.000	1.6
GTEx	Whole Blood	1	0.050	1.6
CommonMind	Brain Pre-frontal Cortex	6	0.112	1.6
The Cancer Genome Atlas	Colon Adenocarcinoma	1	0.048	1.6
The Cancer Genome Atlas	Esophageal Carcinoma	0	0.000	1.6
The Cancer Genome Atlas	Glioblastoma Multiforme	1	0.098	1.6
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	0	0.000	1.6
GTEx	Adrenal Gland	0	0.000	1.5
GTEx	Artery Coronary	1	0.085	1.5
GTEx	Brain Frontal Cortex BA9	0	0.000	1.5
GTEx	Brain Hippocampus	0	0.000	1.5
GTEx	Brain Nucleus accumbens basal ganglia	1	0.116	1.5
GTEx	Esophagus Gastroesophageal Junction	1	0.069	1.5
GTEx	Heart Left Ventricle	0	0.000	1.5
GTEx	Small Intestine Terminal Ileum	0	0.000	1.5
GTEx	Stomach	0	0.000	1.5
METSIM	Adipose	5	0.108	1.5
NTR	Blood	4	0.167	1.5
ROSMAP	Brain Pre-frontal Cortex	2	0.046	1.5
YFS	Blood	1	0.022	1.5
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	1	0.060	1.5
The Cancer Genome Atlas	Breast Invasive Carcinoma	2	0.045	1.5
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	0	0.000	1.5
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	2	0.073	1.5
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	4	0.098	1.5
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	2	0.098	1.5
The Cancer Genome Atlas	Brain Lower Grade Glioma	3	0.070	1.5
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	0	0.000	1.5
The Cancer Genome Atlas	Lung Adenocarcinoma	2	0.068	1.5
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	0	0.000	1.5
The Cancer Genome Atlas	Prostate Adenocarcinoma	1	0.022	1.5
The Cancer Genome Atlas	Soft Tissue Sarcoma	0	0.000	1.5
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.5
The Cancer Genome Atlas	Testicular Germ Cell Tumors	1	0.078	1.5
The Cancer Genome Atlas	Thyroid Carcinoma	2	0.039	1.5
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.5
GTEx	Brain Caudate basal ganglia	0	0.000	1.4
GTEx	Brain Hypothalamus	0	0.000	1.4
GTEx	Brain Putamen basal ganglia	0	0.000	1.4
GTEx	Liver	1	0.139	1.4
GTEx	Uterus	0	0.000	1.4
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	1	0.040	1.4
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	0	0.000	1.4
The Cancer Genome Atlas	Rectum Adenocarcinoma	0	0.000	1.4
The Cancer Genome Atlas	Stomach Adenocarcinoma	0	0.000	1.4